Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pasithea Therapeutics Corp.KTTA · Entity 7685 | 10% owner | October 22, 2022 | February 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pasithea Therapeutics Corp.
Report date October 22, 2022 · Filed February 14, 2023
Jointly reported with PD Joint Holdings, LLC Series 2016-A, Manning Paul B, Tiger Lily Capital, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,608,696 |
Reported balance
Holding disclosure · report date 2022-10-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,608,696 |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-06-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-10-22 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
No transactions match
Try broader filters. Historical coverage is still being backfilled.
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.